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OBJECTIVES We sought to assess the relationship between maximum left ventricular (LV) wall thickness
and outcome in patients with hypertrophic cardiomyopathy (HCM).
BACKGROUND An association between maximum LV wall thickness and risk of sudden death was suggested
in HCM. This finding requires further investigation, given the important implications for risk
stratification and treatment.
METHODS We analyzed the mortality and risk profile of 237 patients (age 41  17 years; 63% male)
classified into five groups based on echocardiographic maximum LV thickness.
RESULTS During follow-up (12  7 years), 36 patients died of cardiovascular causes, including 16
sudden deaths. Maximum LV thickness was not associated with a risk of sudden death (p 
0.37) nor with overall cardiovascular mortality (p  0.7). With the exception of the small
subset with thickness values 15 mm, with a consistently benign clinical course, the
distribution of sudden death and overall cardiovascular mortality was not significantly
different among the other four classes, ranging from 16 to 19 mm to 30 mm. Among 30
patients with extreme LV thickness (30 mm), only one sudden event occurred among six
patients diagnosed at 18 years of age (17%) and none among 24 diagnosed at 18 years of
age. The prevalence of nonsustained ventricular tachycardia, syncope, an abnormal blood
pressure response to exercise, and atrial fibrillation was similar among the five thickness
classes.
CONCLUSIONS During 12-year follow-up, we observed no association between maximum LV thickness and
cardiovascular mortality in a community-based population with HCM. The degree of
maximum LV wall thickness should be considered in the context of a multifactorial approach
to risk stratification, rather than as an isolated risk factor. Only in those patients diagnosed
at a very young age might the presence of extreme LV wall thickness represent, per se, a
potential marker of risk of sudden death. (J Am Coll Cardiol 2003;41:315–21) © 2003 by
the American College of Cardiology Foundation
Sudden death and heart failure (HF) are the most common
causes of death in patients with hypertrophic cardiomyop-
athy (HCM) (1–5). To this day, the identification of
patients at high risk remains a major challenge, as the
predictive value of several potential markers of risk is
disappointingly low. A direct relationship between maxi-
mum left ventricular (LV) wall thickness and risk of sudden
or HF-related death has recently been reported (6). In
particular, extreme wall thickness (i.e., 30 mm) has been
advocated as a major risk factor for sudden death (7) and
consequently suggested as a potential indication for an
implantable cardioverter-defibrillator (6). However, evi-
dence from other studies is controversial and does not seem
to support aggressive treatment based solely on the degree of
LV hypertrophy (2,3,8,9). Therefore, further investigation
is required in different patient populations, given the im-
portant implications for risk stratification and treatment. In
the present study, we analyzed the prognosis of a large
community-based patient cohort over an extended period of
follow-up, with respect to maximum LV wall thickness
measured at diagnosis.
METHODS
Selection of patients. The study group comprised 237
consecutively enrolled and prospectively followed patients
with HCM, predominantly from the region of Tuscany and
Umbria in central Italy. Their age at diagnosis was 41  17
years, and 71% were male (Table 1). The period of
follow-up from first hospital evaluation for the overall study
group was 12  7 years; during this period, patients were
followed regularly, usually at one-year intervals (3). Man-
agement strategies employed for the study groups over the
years have been previously described (3,10,11). Of note,
asymptomatic patients were not thought to require drug
treatment, except in the presence of additional clinical
variables regarded as risk factors for either sudden death,
such as repetitive, nonsustained runs of ventricular tachy-
cardia (treated with amiodarone), or long-term clinical
From Cardiologia S. Luca, Azienda Ospedaliera Careggi, Florence, Italy. This
study was supported by the Italian Ministry for Scientific and Technologic Research
(MURST-COFIN 2002).
Manuscript received February 19, 2002; revised manuscript received July 16, 2002,
accepted August 26, 2002.
Journal of the American College of Cardiology Vol. 41, No. 2, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Science Inc. PII S0735-1097(02)02713-4
deterioration and HF, such as severe rest outflow obstruc-
tion (6) (treated with beta-adrenergic blocking agents).
Echocardiography. Echocardiographic studies were per-
formed with commercially available Hewlett-Packard and
Toshiba instruments. Left ventricular hypertrophy was as-
sessed with two-dimensional echocardiography, and the site
and extent of maximum wall thickness were identified (7).
The peak instantaneous LV outflow gradient was estimated
with continuous wave Doppler under basal conditions (12).
Classes of hypertrophy. The outcome and individual risk
profile of the 237 study patients were assessed based on their
maximum LV thickness value, as measured on the first visit
at our institution, usually at the time of the first diagnosis of
HCM. Patients were divided into five classes according to
maximum LV wall thickness: 15 mm, 16 to 19 mm, 20 to
24 mm, 25 to 29 mm, and 30 mm. To obtain comparable
data, these values were deliberately taken from a recent
study performed on a large HCM patient cohort similar to
ours in terms of demographic features, management strat-
egies, and cardiovascular mortality rates (6).
Definitions HYPERTROPHIC CARDIOMYOPATHY. The di-
agnosis of HCM was based on the two-dimensional echo-
cardiographic identification of a hypertrophied, nondilated
LV (wall thickness 15 mm in adults, and the equivalent
relative to body surface area in children), in the absence of
another cardiac or systemic disease capable of producing the
magnitude of wall thickening evident (2).
MODE OF DEATH. For survival analysis, two modes of
HCM-related death were defined (2): 1) sudden and unex-
pected death: collapse occurring in the absence or within1
h of the onset of symptoms in patients who previously
experienced a relatively stable or uneventful course (includ-
ing resuscitated cardiac arrest and appropriate implantable
defibrillator interventions); and 2) HF-related death due to
progressive cardiac decompensation or directly related to
complications of HF, such as stroke (including patients with
a heart transplant).
Statistical methods. Data are expressed as the mean value
 SD. The Student t test or one-way analysis of variance, as
appropriate, was employed for comparison of normally
distributed data. The chi-square test was utilized to com-
pare noncontinuous variables expressed as proportions. Uni-
variate and multivariate analyses were performed with the
Cox proportional hazard regression model. Survival curves
were constructed according to the Kaplan-Meier method.
Linear trend in survival distributions across the different
classes of LV wall thickness was tested using the log-rank
test. All analyses were performed using the SPSS 8.0
statistical package (SPSS Inc., Chicago, Illinois).
RESULTS
Degree and distribution of maximum LV thickness values.
General clinical and demographic data for the overall study
group are reported in Table 1. The mean value of maximum
LV thickness for the overall study group was 23  5 mm
(range 13 to 42). Figure 1 shows the distribution of the five
classes of LV thickness in different age groups at diagnosis.
Overall, 30 patients (13%) had a maximum LV thickness
30 mm: the proportion of these patients with extreme
thickness values showed a decline after age 30, although this
was not statistically significantly (overall p  0.18) (Fig. 1).
Of these 30 patients with extreme LV thickness, 17 (57%)
were 50 years old at the end of follow-up, and six (20%)
were or60 years old. At the other end of the spectrum, 10
patients had maximum LV thickness 15 mm at the time
of HCM diagnosis. These patients were either in the
pediatric age range (18 years; n  6) or affected relatives
of patients with an unequivocal diagnosis of HCM (n  4)
(13).
Differential features among thickness classes. A compar-
ison of the principal clinical and instrumental findings
among the five thickness classes showed that patients with
mild hypertrophy (15 and 16 to 19 mm) were, on average,
Abbreviations and Acronyms
HCM  hypertrophic cardiomyopathy
HF  heart failure
LV  left ventricular
Table 1. Clinical and Demographic Features of 237 Patients
With HCM
Age at initial evaluation (yrs) 41  17
Age at end of follow-up (yrs) 56  23
Male gender 170 (63%)
NYHA class III/IV at diagnosis 24 (10%)
NYHA class III/IV at end of follow-up 56 (23%)
Duration of follow-up (years) 12  7
Outflow pressure gradient  30 mm Hg* 46 (19%)
Atrial fibrillation 60 (25%)
Family history of HCM and sudden death 35 (15%)
Syncope 34 (14%)
NSVT 91 (38%)
ABPR to exercise 51 (26%)†
Receiving beta-blocking agents 104 (43%)
Receiving verapamil 94 (39%)
Receiving amiodarone 75 (32%)
Receiving other anti-arrhythmics‡ 37 (15%)
Dual-chamber pacing (for gradient/symptoms) 1 (0.4%)
Implantable defibrillator 6 (2%)
Myotomy-myectomy (or MVR) 8 (3%)
Maximum LV wall thickness (mm) 23  5
LVED (mm) 42  9
Left atrium (mm) 40  10
No. of HCM-related deaths, total 36 (15%)
Sudden (including resuscitated cardiac arrest and
appropriate ICD interventions)
16 (7%)
HF-related (including stroke and heart transplant) 20 (8%)
*Peak instantaneous outflow gradient estimated by continuous wave Doppler. †Cal-
culated for 192 patients who underwent exercise testing. ‡Including disopyramide,
sotalol, quinidine, and propafenone. Data are presented as the mean value  SD or
number (%) of patients.
ABPR  abnormal blood pressure response; HCM  hypertrophic cardiomyop-
athy; HF  heart failure; ICD  implantable cardioverter-defibrillator; LV  left
ventricular; LVED  left ventricular end-diastolic cavity dimension; MVR  mitral
valve replacement; NSVT  nonsustained ventricular tachycardia; NYHA  New
York Heart Association.
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younger at diagnosis, had a lower prevalence of atrial
dilation, outflow obstruction, and severe symptoms, and less
often required treatment with beta-blockers or amiodarone
(Table 2). However, the remaining classes of patients with
moderate or severe degrees of maximum LV wall thickness
(20 to 24 mm to 30 mm) were comparable in terms of
clinical features, associated risk factors, and pharmacologic
treatment (Table 2).
HCM-related mortality. During follow-up, 36 patients
died of cardiovascular causes: 16 due to sudden unexpected
death (including resuscitated cardiac arrest) and 20 due to
HF and its complications (including stroke) (Table 1).
Seven additional patients died of noncardiovascular causes.
On average, patients with HCM-related death were more
symptomatic, had larger atria, and more often had atrial
fibrillation, as compared with those who survived, but were
otherwise similar with regard to the other baseline features,
including maximum LV wall thickness (24  4 vs. 23  5
mm, p  NS). Overall cardiovascular mortality and sudden
death rates were 1.3% and 0.6% per year, respectively. The
mean age at the time of death was 56  23 years; patients
dying suddenly were significantly younger than those with
HF-related or stroke death (34  21 vs. 48  17 years, p 
0.05). Of note, seven sudden deaths occurred among the 75
patients receiving amiodarone (9%).
Impact of maximum LV wall thickness on outcome.
Cardiovascular mortality rates for the five classes of LV
thickness are shown in Table 2. No deaths occurred among
patients with LV thickness 15 mm. Among the other
thickness classes, annual cardiovascular mortality ranged
Figure 1. Distribution of maximum left ventricular (LV) thickness among 237 patients with hypertrophic cardiomyopathy (HCM), according to age. The
stacks in each bar represent the percentage of patients in each age group and LV thickness class at the time of the first diagnosis of HCM.
Table 2. Clinical Features, Risk Profile, and Mortality Rates Among the Five LV Thickness Classes
< 15 mm
(n  10)
16–19 mm
(n  56)
20–24 mm
(n  94)
25–29 mm
(n  47)
> 30 mm
(n  30)
Overall
p Value
Age at diagnosis (years) 25  13 40  16 44  15 43  17 38  19 0.05*
Follow-up (years) 9.3  6.1 9.9  6.2 12.1  6.7 12.4  7.2 12.4  8.0 0.2
Left atrium (mm) 26  15 39  8 42  8 43  10 42  9  0.01*
LV end-diastolic dimension (mm) 37  13 43  10 42  7 43  8 40  5  0.05*
LV outflow tract obstruction
(peak gradient 30 mm Hg)
0 3 (5%) 18 (19%) 11 (23%) 14 (47%)  0.001*†
NYHA III/IV at diagnosis 0 2 (4%) 13 (14%) 4 (8%) 5 (17%)  0.01*
NYHA III/IV at end of follow-up 0 5 (9%) 26 (28%) 19 (40%) 6 (20%) 0.005*‡
Syncope 2 (20%) 7 (12%) 13 (14%) 5 (11%) 7 (23%) 0.6
NSVT 1 (10%) 15 (27%) 41 (44%) 20 (42%) 14 (47%) 0.9
ABPR 3 (30%) 11 (19%) 21 (22%) 8 (17%) 8 (27%) 0.6
Atrial fibrillation 0 10 (18%) 26 (28%) 17 (36%) 7 (23%) 0.2
Receiving beta-blocking agents 2 (20%) 14 (25%) 44 (47%) 27 (57%) 17 (57%)  0.05§
Receiving amiodarone 1 (10%) 9 (16%) 32 (34%) 21 (45%) 12 (40%)  0.02§
Total cardiovascular deaths 0 7 (13%) 15 (16%) 10 (21%) 4 (13%) 0.7
Sudden deaths 0 6 (11%) 5 (5%) 4 (8%) 1 (3%) 0.3
HF/stroke-related 0 1 (2%) 10 (11%) 6 (13%) 3 (10%) 0.7
*p 0.05 for  15 mm versus other classes at post hoc analysis. †p  0.05 for  30 mm versus other classes. ‡p  0.05 for 25–29 mm versus other classes. §p  0.05 for 
15 and 16–19 mm versus other classes. Data are presented as the mean value  SD or number (%) of patients.
Abbreviations as in Table 1.
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from 1.1% to 1.7%, with no significant excess in any class
(Fig. 2, Table 2) . The rate of sudden and unexpected death
ranged from 0.3% to 1.1% per year; the lowest value was
recorded in the group of 30 patients with maximum LV
thickness 30 mm (Table 2). In this group with extreme
LV hypertrophy, only one sudden event occurred during
12-year follow-up (i.e., resuscitated cardiac arrest with
documented ventricular fibrillation in 1 of the 6 patients
diagnosed in the pediatric age range [18 years]). Con-
versely, no sudden deaths or cardiac arrests (including
appropriate implantable cardioverter-defibrillator dis-
charges) occurred among the 24 patients with extreme LV
hypertrophy diagnosed at age 18 years.
Univariate survival analysis showed no association be-
tween maximum LV wall thickness and overall cardiovascular
mortality (p  0.37) (Fig. 3) or sudden death (p  0.27).
Functional limitation, acute events, and arrhythmias.
The individual risk profile was analyzed in study patients by
assessing the most important potentially adverse prognostic
markers, including a family history of sudden death, syn-
cope, multiple and repetitive nonsustained ventricular tachy-
cardia on Holter electrocardiography, and atrial fibrillation. In
the present study cohort, all of these factors were relatively
uniformly distributed among the five thickness classes, and
there was no trend suggesting a progressively more severe risk
profile with greater maximum LV wall thicknesses (Table 2).
In particular, none of these indicators of risk had a significantly
higher prevalence among patients with extreme LV hypertro-
phy, as compared with other classes (Table 2).
DISCUSSION
Controversies over the prognostic role of maximum LV
thickness. The debate as to whether the magnitude of LV
hypertrophy has an influence on prognosis in HCM patients
spans almost 20 years and has produced conflicting results
(2,3,5–9,14). Recently, two large studies have reported a
direct relationship between maximum LV wall thickness
and risk of HCM-related mortality, particularly due to an
increase in sudden and unexpected death (6,8). In both
studies, risk appeared to be particularly high in the small
subsets of patients with maximum LV thickness 30 mm.
However, even extreme degrees of maximum LV wall
thickness showed a disappointingly low positive predictive
accuracy (6,8). Thus, the prognostic implications of the
magnitude of LV hypertrophy remain controversial. This
issue is of relevance because extreme LV hypertrophy has
been suggested as a potential indication, per se, for aggres-
sive prophylactic treatment in HCM patients (6). For this
reason, we chose to assess cardiovascular mortality and
individual risk profile with respect to maximum LV hyper-
trophy in a large, consecutively enrolled and prospectively
followed community-based patient population with HCM.
Left ventricular wall thickness and HCM-related mor-
tality. In the present study, the severity of hypertrophy
expressed as maximum LV wall thickness did not represent
a significant prognostic indicator in HCM patients, as no
trend was observed suggesting an increasing long-term risk
of overall mortality, sudden death, or HF-related death for
increasing degrees of maximum LV wall thickness. Indeed,
with the exception of the small subset with thickness values
15 mm, with a consistently benign clinical course, the
distribution of sudden death and overall cardiovascular
mortality was not significantly different in the other four
thickness classes ranging from 16 to 19 to 30 mm. A
benign prognosis among patients with maximum LV thick-
ness15 mm is a constant finding (6,8). However, we agree
with Elliott et al. (5,8) that even mild degrees of hypertro-
Figure 2. Annual rates of cardiovascular mortality according to maximum
left ventricular (LV) thickness at diagnosis. Solid bars  total cardiovas-
cular mortality; shaded bars sudden death; open bars congestive heart
failure/stroke-related death.
Figure 3. Kaplan-Meier curves showing cumulative survival according to
maximum left ventricular (LV) thickness. Survival free of cardiovascular
mortality is shown for four different thickness classes. Because no event
occurred in patients with maximum LV thickness 15 mm, this particular
subgroup was excluded from the analysis, for added clarity. A comparison
of survival curves showed that there was no trend toward increasing
mortality for increasing values of maximum LV wall thickness.
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phy cannot be used to reassure patients, but must be seen in
the context of a multifactorial approach to risk stratification.
Among patients with extreme LV hypertrophy (30
mm), total cardiovascular mortality and sudden death rates
were lower or equal to those in the three classes ranging
from 16 to 29 mm. The only sudden event in this group was
cardiac arrest associated with ventricular fibrillation in a
patient diagnosed at 18 years of age, whereas no sudden
deaths nor resuscitated cardiac arrests occurred among adult
patients. Our findings, however, are not in disagreement
with the report by Spirito et al. (6), in which the increase in
risk among patients with extreme LV hypertrophy was also
confined to those individuals diagnosed at18 years of age,
whereas mortality rates among patients diagnosed during
adulthood was relatively low (7%) and comparable to those
of patients with only mild hypertrophy. Indeed, a combined
analysis of the three existing studies consistently shows that,
among patients with extreme LV thickness, an increased
risk of sudden death is confined to those diagnosed at a very
young age (Table 3). Conversely, in adult patients, even
extreme maximum LV thickness does not seem to represent
a meaningful predictor of risk and should not lead to
aggressive management in the absence of other documented
risk factors (5). This conclusion is supported by two addi-
tional observations originating from this study. First of all,
we did observe a declining prevalence of patients with
extreme hypertrophy who were 30 years old, as also
reported by the other two studies (6,8), which may suggest
reduced survival in this particular group. However, this
trend was not statistically significant and should be inter-
preted with caution, as other explanations such as the
occurrence of LV remodeling with a progressive decrease in
LV thickness should also be considered (15). In our patient
population, maximum LV wall thickness 30 mm was not
incompatible with a normal life-expectancy, nor was it
associated with an increase in disease-related complications
over an average period of follow-up of 12 years. Moreover,
the overall risk profile of patients with massive hypertrophy,
assessed by the main established risk factors for HCM, did
not show significant differences among thickness classes.
Indeed, none of the most relevant markers of electrical or
hemodynamic instability, including syncope, nonsustained
ventricular tachycardia, abnormal blood pressure response to
exercise, and atrial fibrillation (1,8,10,16), were significantly
associated with the degree of maximum LV thickness.
Therefore, although greater degrees of LV hypertrophy may
theoretically predispose to a higher likelihood of arrhyth-
mogenic foci due to disarray, subendocardial ischemia, and
fibrosis (8), no direct relationship was found between
maximum LV thickness and clinical evidence of arrhythmic
risk.
Comparison with previous studies. In the present study,
the sudden death rate observed among patients with ex-
treme LV thickness (30 mm) was six to seven times lower
than those reported by two other recent and extensive
studies based on large HCM populations (6,8) (Table 3), Ta
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despite similar clinical features in the three cohorts (includ-
ing a similar proportion of patients with maximum LV
thickness 30 mm) and comparable cardiovascular mortal-
ity ranging from 1.2% to 2% per year. Furthermore, al-
though our study group was smaller, the average follow-up
duration was almost double that of the other two studies,
thus covering a comparable number of patient-years in the
subgroup with extreme LV thickness (Table 3).
Potentially accounting for a more benign prognosis in our
subset with LV thickness 30 mm, is the smaller propor-
tion of patients diagnosed in the pediatric age range, as
compared with the other two studies (Table 3). In this
respect, our results are not incompatible with the two
previous studies, but rather support the lack of predictive
accuracy of extreme LV thickness among adult patients, as
compared with children and adolescents. Moreover, the
widespread use of amiodarone in our HCM population
(32%) may partly account for the discrepancy observed with
the study by Spirito et al. (6) (6% of patients on amiodarone
treatment), although not with that by Elliott et al. (8)
(28%). In the present study, the extensive use of anti-
arrhythmic drugs, particularly amiodarone, may have played
a role in determining the favorable clinical outcome and
preventing sudden cardiac death, by both suppressing ven-
tricular tachyarrhythmias and preventing atrial fibrillation
(11,16). Nevertheless, such an effect is not quantifiable. Of
note, 9% of the study patients receiving amiodarone died
suddenly during follow-up. In the two previously quoted
studies, this value was 17% (6) and 3% (8). Although these
discrepancies are not easy to interpret and may reflect
differences in the selection of patients for treatment, all
studies indicate that amiodarone does not convey absolute
protection from sudden death.
To date, primary prevention of sudden death remains
extremely challenging in HCM patients. The most appro-
priate approach based on current knowledge is necessarily
multifactorial, because each of the presently known predic-
tors of risk, including maximum LV wall thickness30 mm
(in younger patients), a family history of sudden death, an
abnormal blood pressure response to exercise, nonsustained
ventricular tachycardia, and unexplained syncope, has very
low positive predictive accuracy on an individual basis (5).
Moreover, important potential risk factors, such as LV
outflow obstruction and demonstrable myocardial ischemia,
still require adequate prognostic assessment in HCM.
Qualitative evaluation of hypertrophy in HCM. A lim-
itation of the present study, which is shared by the other
studies on the subject (6,8), is that a single measurement of
maximum LV thickness, although reproducible and practi-
cal for clinical purposes, does not accurately reflect the total
burden of hypertrophy in individual patients and thus
represents only a crude estimate of the morphologic severity
of HCM. Unfortunately, due to the highly asymmetric
morphology of the LV in HCM patients, formulas devised
to more accurately assess the total extent of ventricular mass
cannot be satisfactorily applied in this disease (17). More-
over, a quantitative approach to hypertrophy is necessarily
limited in that it overlooks individual differences in the LV
wall structure. Indeed, several pathophysiologic substrates
coexisting in the hypertrophic myocardium, including dis-
array, fibrosis, and ischemia, are possibly more relevant than
the extent of hypertrophy itself in determining HCM-
related risk and ideally require a comprehensive assessment
in each patient (18–20). For example, a severe reduction
and transmural maldistribution of myocardial blood flow,
which have been clearly demonstrated in HCM patients
with massive LV hypertrophy (20), are strongly predictive of
an adverse long-term outcome, irrespective of individual
maximum LV thickness values (21).
Conclusions. In the course of a 12-year average follow-up
period, there was no significant association between the
severity of LV hypertrophy and the risk of sudden death or
overall cardiac mortality in our community-based popula-
tion with HCM. Thus, our results support the view that the
degree of maximum LV wall thickness should be considered
in the context of a multifactorial approach to risk stratifi-
cation in HCM patients, rather than as an isolated risk
factor. However, a likely exception is represented by patients
diagnosed at a very young age, in whom the presence of
massive LV hypertrophy might be considered, per se, as a
potential marker of increased risk for sudden death.
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